AMALY — SHARIAH COMPLIANCE REPORT ================================== Symbol: CMMB Report Date: 2026-07-02 Full Report: https://amaly.io/stock/CMMB EXECUTIVE SUMMARY ------------------ Compliance Status: NON_COMPLIANT Quality Rating: B Description: Chemomab Therapeutics Ltd. (CMMB) is a clinical-stage biotechnology company focused on developing therapeutics for inflammation and fibrosis, operating in the Healthcare sector. This analysis evaluates its Shariah compliance through financial screening, business activities, ESG factors, and index inclusions as of 2026-02-28. Financial ratios show strong compliance with low debt (0.68%) and liquidity (24.52%), and no non-permissible income identified. However, the company is not included in any major Shariah indices due to its small market capitalization, leading to an overall non-compliant status. ESG risks are low, with ethical medical research aligning with Islamic principles, though geopolitical location in Israel warrants monitoring. Primary Compliance Concerns: - Not included in any major Shariah indices due to small market cap - Geopolitical risks from operations in Israel - Insufficient detailed income data for full verification Purification Requirement: 0.00% Index Inclusion: Not included in S&P Dow Jones Shariah, MSCI Islamic, FTSE Shariah, or DJIM indices. KEY FINANCIAL METRICS ---------------------- Debt Ratio: 0.0% Liquidity Ratio: 24.5% Interest Income Ratio: 0.0% Purification Required: 0.00% INDEX INCLUSION STATUS ----------------------- S&P Shariah: INCLUDED MSCI Islamic: INCLUDED DJIM: INCLUDED FTSE Shariah: INCLUDED Total: 4 of 4 Last Verified: 2025-09-30 REPORTING PERIOD ----------------- Latest Annual Report: FY 2025 Latest Quarterly Data: Q4 2025 Trend Period: FY 2020 to FY 2025 Data Retrieved: 2026-02-28T12:00:00Z --- Full interactive report: https://amaly.io/stock/CMMB Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.